Biocryst Pharmaceuticals Inc (BCRX)
R&D to Revenue
23.81%
Quarterly · Period ending:
BCRX R&D to Revenue
Latest reported23.81%period ending
Latest reported23.81%period ending
BCRX Quarterly R&D/Revenue (0.00% → 23.81%)
Latest values, visible window
High-resolution chart · PNG
BCRX r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 23.8117% | |
| 38.5639% | |
| 10.1344% | |
| 27.7725% | |
| 26.5597% | |
| 25.6091% | |
| 37.588% | |
| 35.0865% | |
| 34.4117% | |
| 50.1213% | |
| 75.0013% | |
| 54.0442% | |
| 62.1244% | |
| 70.3539% | |
| 92.0322% | |
| 69.5531% | |
| 94.595% | |
| 130.9216% | |
| 134.7152% | |
| 121.8983% | |
| 105.8328% | |
| 222.6507% | |
| 880.3287% | |
| 495.6572% | |
| 957.7847% | |
| 619.2619% | |
| 67.3984% | |
| 1,415.2113% | |
| 1,911.6713% | |
| 467.0121% | |
| 858.5929% | |
| 1,513.4801% | |
| 168.1607% | |
| 463.8078% | |
| 435.0643% | |
| 199.8744% | |
| 508.5189% | |
| 177.7048% | |
| 135.3445% | |
| 181.6952% | |
| 295.9265% | |
| 426.9502% | |
| 413.8853% | |
| 182.6431% | |
| 63.9424% | |
| 250.8057% | |
| 339.8825% | |
| 402.5942% | |
| 754.9113% | |
| 265.5581% | |
| 147.7619% | |
| 333.9054% | |
| 1,428.5018% | |
| 208.5256% | |
| 270.4218% | |
| 209.547% | |
| 303.4917% | |
| 126.3481% | |
| 291.1753% | |
| 281.425% | |
| 374.1633% | |
| 237.9393% | |
| 141.4972% | |
| 159.975% | |
| 193.5005% | |
| 95.5736% | |
| 57.5977% | |
| 172.3644% | |
| 234.2386% | |
| 258.9814% | |
| 64.4258% | |
| 179.8516% | |
| 502.9334% | |
| 203.3618% | |
| 103.3441% | |
| 145.2866% | |
| 141.4237% | |
| 176.8206% | |
| 535.3592% | |
| 930.1676% | |
| 718.2285% | |
| 1,043.1907% | |
| 28,947.0312% | |
| 22,387.5% | |
| 9,074.1379% | |
| 12,621.9512% | |
| -1,419.5488% | |
| 1,791.8519% | |
| 2,003.6866% | |
| 2,753.0387% | |
| 353.58% | |
| 1,398.6486% | |
| 1,114.6617% | |
| 808.1169% | |
| 700.227% | |
| 769.9029% | |
| 949.4577% | |
| 999.4434% | |
| 146.6996% | |
| 83.2353% |